AbbVie (ABBV) Pipeline Bolstered as FDA Approves Mavyret Label Expansion for Hepatitis C

AbbVie Inc. (NYSE:ABBV) is one of the 12 best healthcare stocks to buy now. On June 12, the US Food and Drug Administration (FDA) approved the company’s Mavyret treatment label expansion. The approval makes the treatment the first antiviral therapy for people with Acute Hepatitis C Virus (HCV).

A closeup of a medical technician handling a sample of a biopharmaceutical drug.

The FDA agreed to a label expansion following positive data from a late-stage study evaluating the drug’s effectiveness in adults with acute HCV infection. The adverse events identified in the treatment were mild or moderately severe, including fatigue, asthenia, headache, and diarrhea.

The label expansion comes when the US is expected to incur around $120 billion in medical costs over the next 10 years. Most of the costs would be linked to chronic liver disease and other related conditions associated with HCV. Mavyret generated $306 million in sales in the first quarter of the year, including $142 million in the US.

AbbVie Inc. (NYSE:ABBV) is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines and solutions to address complex health issues. Its research and development efforts target areas like immunology, oncology, virology, and neuroscience.

While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Stocks Analysts Are Upgrading Today and 13 Best AI Stocks to Buy Under $10.

Disclosure: None.